Role of Sphingosine-1-phosphate Receptors in Cytokine and Chemokine Production by Glia by Moon, Jean
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2018 
Role of Sphingosine-1-phosphate Receptors in Cytokine and 
Chemokine Production by Glia 
Jean Moon 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 
© Jean Moon 
Downloaded from 
https://scholarscompass.vcu.edu/etd/5535 
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has 
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. 
For more information, please contact libcompass@vcu.edu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROLE OF SPHINGOSINE-1-PHOSPHATE RECEPTORS IN CYTOKINE AND 
CHEMOKINE PRODUCTION BY GLIA 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Pharmacology and Toxicology at Virginia Commonwealth University.  
 
 
 
 
 
 
by 
Jean Moon, B.S. 
University of Virginia 2014 
 
 
 
 
Director: Kurt F. Hauser, Ph.D.  
Professor 
 Department of Pharmacology and Toxicology 
 
 
 
 
 
 
 
 
Virginia Commonwealth University  
Richmond, Virginia  
June, 2018
 ii 
Acknowledgements 
I would like to express my sincere gratitude to the individuals who have guided me 
through my project and growth as a scientist. Foremost, I would like to thank my 
advisor, Dr. Kurt F. Hauser for the continuous support and patience. Your enthusiasm 
for science has inspired and enriched me as a researcher. 
 
I would also like to thank my committee members: Dr. Pamela Knapp and Dr. Laura 
Sim-Selley for their encouragement, insightful comments, and challenging questions. I 
am grateful to all of those with whom I have had the pleasure to learn and work with 
during this time. 
 
Last but not least, I would like to thank my family for all of their support, patience, and 
love. 
 
 
  
 iii 
ABSTRACT 
About 1 in 10 newly diagnosed HIV cases in the United States are attributed to 
injection drug abuse. Opiate abuse exacerbates HIV disease progression in the central 
nervous system by disrupting glial function and significantly augmenting glial-derived 
pro-inflammatory mediators. Astroglia and microglia exposed to viral proteins, such as 
transactivator of transcription (Tat), become activated leading to release of a large 
number of cytokines and chemokines and a positive loop of neuro-inflammation. 
Despite effective antiretroviral therapy, persistent inflammation and immune activation 
affect HIV-infected individuals. A potential alternative target is sphingosine 1-phosphate 
receptor 1 (S1PR1) which is known to play a role in proliferation and trafficking of 
immune cells. In addition, the S1P-S1PR1 ligand-receptor axis induces NF-κB activation 
and pro-inflammatory cytokine production in astrocytes. The drug FTY720 (fingolimod) 
acts at S1PR1,3,4,5 and its therapeutic effects are thought to result from the drug’s ability 
to cause receptor internalization and degradation thereby acting as a functional 
antagonist. The purpose of this study was to assess if S1PR1 modulation by FTY720 
regulates cytokine levels in the context of downstream astroglial activation induced by 
HIV-1 Tat ± morphine. Pretreatment of primary murine glial cultures with FTY720 results 
in dose-dependent inhibition of Tat±morphine induced increases in IL-6, CCL2, CCL3, 
and CCL4 levels. A selective 1 antagonist, W146, blocked these increases providing 
evidence that indeed the significant reduction in cytokine levels was mediated through 
S1PR1. In comparison SEW 2871, a S1PR1 agonist that leads to receptor recycling 
upon internalization instead of ubiquitination/degradation, was used to examine if 
receptor downregulation is responsible for attenuated cytokine release. Glia that were 
 iv 
pretreated with SEW 2871 for a shorter duration prior to treatment with Tat or morphine 
displayed time-dependent reduction in cytokine secretion. Contrastingly, cells pre-
exposed to SEW 2871 for a longer period demonstrated elevated protein levels, 
suggesting the differential fate of receptor after internalization is involved in regulating 
the inflammatory response. 
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Chapter 1 
INTRODUCTION TO HIV-1 IN THE CENTRAL NERVOUS SYSTEM 
1.1 HIV and AIDS Epidemic Overall 
 At the end of 2016, approximately 36 million individuals worldwide and 1.1 million 
people in the United States are estimated to be currently living with Human 
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS). Around two 
million individuals around the world became newly infected with HIV in the past year 
(CDC, 2017; UNAIDS 2018). In the United States, HIV is mainly transmitted through 
sexual behaviors and sharing needles or syringes that have been used to inject drugs. 
Ten percent of HIV infections globally can be attributed to injecting drugs, and thirty 
percent of this population is outside of Africa. Between 2000 and 2016, the number of 
people living with HIV on antiretroviral therapy has increased from less than 1 million to 
18 million (WHO, 2018). Despite the scientific advancements in understanding HIV, 
many people still do not have access to prevention, care, and treatment, and attempts 
to completely eradicate the virus remain in progress. 
 With studies showing that reduced HIV levels in the blood reduces transmission 
of HIV and slows disease progression, the emphasis of drug research and development 
has been on increasing viral suppression. The past year, the federal government has 
invested nearly $27 billion dollars to fund HIV/AIDS programs and research. The 
National HIV/AIDS Strategy (NHAS) focuses on reducing HIV infections, increasing 
access to care, and improving health outcomes for individuals living with HIV. Recent 
data from 2014 has shown that the overall percentage of people diagnosed with HIV 
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who have achieved viral suppression has increased since 2010. However, two groups 
remain to be at a higher risk: youth and injection drug users (HIV GOV, 2018). 
1.2 Virology of HIV-1 
HIV-1 is a lentivirus within the Retroviridae family. The RNA genome contains 
nine genes that encode structural proteins (gag, pol, env), regulatory proteins (tat, rev), 
and accessory proteins (nef, vpr, vif, vpu) (Sattenteu et al., 1986; Kuiken et al., 2008; 
Frankel et al., 1998) that are critical for infection and viral replication (Muesing et al.,  
1985; Gallo et al.,  1988). The env gene encodes a 160 kDa glycoprotein, gp160, that is 
cleaved to generate viral envelope proteins gp120 and gp41 which are crucial for fusion 
between viral and host cell membranes (Kuiken et al., 2008; Checkley et al., 2011). The 
first step of HIV infection is binding of gp120 primarily to CD4 receptors on the surface 
of the target cell. Alternatively, infection can be initiated when gp120 interacts binds to 
the galactosylceramide (GalCer) receptors (Cook et al., 1994). Conformational changes 
in gp120 allows co-receptor binding. HIV strains can be broadly classified based on the 
co-receptors involved. Viruses with preferential tropism for CCR5 or CXCR4 chemokine 
co-receptors are termed R5- or X4- tropic HIV, respectively, while viral strain favoring 
both are referred to as dual tropic. Other chemokine receptors, CCR2, CCR3, CX3CR1, 
have also been reported to mediate HIV-1 entry (Garin et al., 2003; He et al., 1997; 
Puissant et al., 2003). Binding to the co-receptor triggers further conformational 
changes that initiates insertion of gp41 into the target membrane leading to complete 
membrane fusion and delivery of the viral genome. After successful infection, the single-
stranded RNA is converted into double-stranded cDNA by reverse transcriptase (Wilen 
et al., 2012; Blumental et al., 2012; Myszka et al.2000). The viral DNA binds to an 
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integrase enzyme and host proteins to form a complex that translocates into the nucleus 
and gets inserted into the host genome (Chiu et al., 2004; Craigie, 2012; Fulcher et al., 
2003).  
1.3 HIV-1 Tat  
Infected cells can transcribe and produce viral proteins such as Tat, gp120, and 
Vpr. The focus of the current studies is on Tat, transactivator of transcription, which has 
either 86 or 101 amino acids encoded by two exons. The first exon forms the 1-72 
amino acid variant (Fulcher et al., 2003; Jeang et al., 1999; Nath et al., 1996). Both the 
mRNA and protein forms of Tat have been detected in HIV-infected patients with 
encephalitis (Hudson et al., 2000). Nanomolar levels of Tat have been found in sera 
during acute infection (Bennasser et al., 2002). Tat has important functions in the 
biological effects of HIV, and it is thought to be involved in the pathogenesis of 
neuroAIDS (Conant et al., 1998). Tat released from infected cells into the extracellular 
environment has a tendency to adhere to the surface of nearby cells by binding to 
heparin sulfate proteoglycans (HSPGs) which facilitates its internalization (Chang et al., 
1997; Christianson et al., 2014). After being taken up by uninfected cells, Tat can 
activate the expression of a number of cellular genes (Feinberg et al., 1991; Ensoli et 
al., 1993). The central role of Tat is not only to activate transcription but also to enhance 
the number of viral transcripts by a hundred-fold (Das et al., 2011; Sakane et al., 2011). 
Transcription of the HIV provirus initially involves binding of many cellular factors 
including TATA box binding protein, nuclear factor-kappa B (NF-kB), RNA polymerase II 
to the 5’ long terminal repeat (LTR) sequence. This generates low levels of viral 
transcripts which are subsequently processed and translated. Tat, which is synthesized 
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early on in replication, actively stimulates transcription by binding to the TAR hairpin 
sequence (Das et al., 2011; Karn et al., 2012).  
HIV-1 Tat potentially acts as a potent chemoattractant for monocytes (Benelli et 
al., 1998; Lafrenie et al., 1996; Mitola et al., 1997). Significant chemotactic potential was 
found in a cysteine-rich peptide, CysL24-51, consisting of the core domains of Tat (Albini 
et al., 1998). This peptide contains a CCF (Cys-Cys-Phe) sequence that is analogous to 
critical sequences of chemokines, a group of molecules that recruit monocytes to sites 
of inflammation (Albini et al., 1998; Alcami et al., 2003). The relation to chemokines was 
highlighted in cross-desensitization studies where Tat displaced CCL2 and CCL3 from 
binding to the b-chemokine receptors CCR2 and CCR3, suggesting Tat and b-
chemokines share common receptor targets. Functionally, Tat mimics chemokines by 
recruiting macrophages/monocytes expressing chemokine receptors and by inducing a 
transient Ca2+ flux comparable to that induced by CCL4. Destabilization in intracellular 
calcium levels can cause release of reactive oxygen species as well as proinflammatory 
cytokines such as TNF-a, IL-6, and IL-1b that collectively drive inflammation (Kutsch et 
al., 2000; El-Hage et al., 2008).  
In monocytes, Tat can induce TNF-α and IL-10 production through both the 
classical and alternative NF-kB pathways contributing to the hyper-activation of the 
immune system. Persistent NF-kB activation occurs in HIV-infected 
monocytes/macrophages, upregulating the expression of NF-kB target genes including 
cytokines and chemokines. The canonical pathway involves phosphorylation of IkB-a 
repressor protein by IkB-a kinase (IKK) which releases the NF-kB complex. Tat 
enhances IKK activity and transcriptional activity of the NF-kB complex (El-Hage et al., 
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2008; Ben Haij et al., 2015; Fiume et al., 2012; Demarchi et al., 1996; Westendorp et 
al., 1995). The alternative pathway depends on NF-kB-inducing kinase (NIK) and IKKa 
instead of the trimeric IKK complex (Leghmari et al., 2008). 
1.4 HIV Infection and the Central Nervous System 
 While the direct actions on the cellular immune system involving depletion of the CD4 
lymphocytes have been widely recognized, HIV-1 also results in neurological complications 
(Carroll et al., 2017). After infection, HIV-1 invades the central nervous system (CNS) and is 
localized in varying concentrations across brain regions. Imaging data revealed that HIV-1 
targets structures associated with driving memory, including the hippocampus and prefrontal 
cortex (Aylward et al., 1995; Castelo et al., 2006; Mcnab et al., 2008). Affected areas such as 
the basal ganglia impairs motor functions (Devaughn et al., 2015). HIV-associated 
neurocognitive disorder (HAND) refers to the spectrum of neurocognitive dysfunction that has 
been categorized as asymptomatic neurocognitive impairment (ANI), mild neurocognitive 
disorder (MND), and HIV-associated dementia (HAD) (Clifford et al., 2013; Saylor et al., 2016; 
Block et al., 2016). With the development of highly active antiretroviral therapy (HAART), the 
life expectancy of HIV-positive populations has improved significantly (Brechtl et al., 2001). 
Despite the reduction in the incidences of moderate to severe dementia, the increasing 
prevalence of milder forms of HAND remains as a substantial source of morbidity. The 
persistent expression of low levels of HIV and chronic inflammation in the central nervous 
system likely contributes to the development of HAND (Carroll et al., 2017; Saylor et al., 2016).  
 Studying HAND pathogenesis is limited since tissues from the CNS are typically only 
attainable post-mortem. As a result, rodent and nonhuman primate models have been used to 
elucidate the mechanisms by which HIV-1 invades the CNS (Evering et al., 2018). The exact 
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mechanism by which HIV-1 crosses the blood-brain barrier (BBB) is still unclear. The “Trojan 
Horse hypothesis” proposes that viruses enter the CNS as a passenger in infected cells 
(Ghafouri et al., 2006; Izquierdo-useros et al., 2010). HIV-1 infected CD4+ T cells and 
monocytes circulating in the blood can cross the BBB and propagate the infection. Chronic 
low-level infection of monocytes establishes persistent viral reservoirs. The monocytes that 
differentiate into macrophages become better substrates for infection and replication and 
produce cytokines/chemokines that activate microglia, astrocytes, and endothelial cells. This 
release of proinflammatory molecules and viral proteins facilitates the upregulation of adhesion 
molecules and the disruption of BBB integrity, promoting further entry of HIV into the CNS 
(Strazza et al., 2011; Williams et al., 2012). Alternatively, HIV-1 entry can take place via trans-
endothelial migration where the virus attaches to an endothelial cell layer, which leads to the 
activation of macrophages expressing adhesion receptors. Ultimately, macrophages can 
adhere to the endothelial cells compromising the BBB and transmigrate into the brain (Maslin 
et al., 2005; Westhorpe et al., 2009). Upon viral entry, the CNS immune cells are the primary 
targets of infection. Perivascular macrophages and microglia are the principal producers of 
HIV-1 in the brain and serve as the main viral reservoirs (Castellano et al., 2017). A small 
proportion of astrocytes are consistently infected in vivo using an unconventional CD4-
independent mechanism (Li et al., 2015). The virus infects glia but not neurons, suggesting 
HIV-1-associated neuronal injury is mediated indirectly through glia (Kovalevich et al., 2012; 
Merrill et al., 1991; Hauser et al., 2007; Hauser et al., 2005; Gendelman et al., 1997; Kaul et 
al., 2001; Deshpande et al., 2005). Dysregulation of glial functions can create an unstable 
environment for neurons. Reactive glia contribute to neuroinflammation by synthesizing and 
secreting active molecules such as cytokines, chemokines, reactive oxygen species (ROS), 
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nitric oxide (NO), and glutamate (Choi et al., 2014; Cisneros et al., 2012; El-Hage et al., 2008). 
1.4.1 Astrocytes  
 Neurons are not directly infected by HIV; however, bystander neurons can 
experience acute damage from exposure to toxic viral proteins (such as Tat, gp120, and 
Vpr) and/or toxic inflammatory products (such as proinflammatory cytokines and 
reactive oxygen and nitrogen species) produced by the infected host glia (Xu et al., 
2004; Nath et al., 2002). Although astrocytes are not productively infected, they are the 
predominant cells in the brain, and they regulate physiological conditions in the CNS. In 
response to viral and cellular toxins secreted from infected cells, astrocytes become 
activated (Russell et al., 2017; Sabri et al., 2003; Fitting et al., 2010; Patton et al., 2000; 
Conant et al., 1998). With persistent neuroinflammation, the ability of astrocytes to 
provide metabolic support to neurons and to regulate BBB integrity is impaired. 
Additionally, astrocytes may fail to maintain homeostasis with changes in expression of 
enzymes and transporters to clear neurotransmitters and neutralize ROS (Blackburn et 
al., 2009). Tat destabilizes concentration of intracellular Ca2+ ([Ca2+]i) in astrocytes and 
modifies gene expression to upregulate the secretion of  cytokines and chemokines 
(CCL2, CCL3, CCL4, IL-6, TNF-a) through a NF-kB-dependent mechanism (El-Hage et 
al., 2006). Additionally, HIV-exposed, reactive astrocytes have a reduced ability to 
buffer glutamate and uptake glutamate from neuronal synapses (Cisneros et al., 2012; 
Ton et al., 2013; Zou et al., 2011). Collectively, neuronal function is compromised due to 
insufficient support by astrocytes and direct toxicity of viral and cellular toxins released 
by infected glia (Fan et al., 2016; Hauser et al., 2014). 
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1.5 Interactions of HIV-1 and opiates in neuroAIDS 
 Opiate injection drug use does not only play a role in increasing the risk of 
transmitting the virus. Importantly, HIV-infected individuals suffering from pain and 
chronic headache symptoms are prescribed opioid medications (Kapadia et al., 2005; 
Robinson-papp et al., 2012). With the opioid system, brain regions such as the striatum 
have a higher concentration of the µ-receptors (MOR) which perhaps accounts for why 
the striatum is particularly susceptible to the combined Tat and morphine neurotoxicity 
(Arvidsson et al., 1995). Morphine exposure has been shown to increase astrocyte 
activation and microglial/macrophage recruitment in the striatum of inducible Tat 
transgenic mice (Bruce-Keller et al., 2008). Evidence suggests that the HIV and 
morphine trigger inflammatory signals between the astroglia and microglia resulting in a 
positive feedback loop. Overall, the interaction between the ongoing infection and 
opioids accelerates neuropathogenesis (Mcmanus et al., 2000; Lowenthal et al., 1989).  
Tat is a soluble viral protein that alone can promote neuroinflammation by 
elevating oxidative stress and upregulating pro-inflammatory cytokines (El-Hage et al., 
2008; El-Hage et al., 2006; Fitting et al., 2010). In vitro studies have demonstrated that 
glia are essential for the interactive effects between Tat and morphine. Addition of 
morphine alone did not exacerbate Tat-induced toxicity in isolated neurons. However, 
synergistic effects between Tat and morphine were emphasized in co-cultures of 
neurons with glia expressing µ-opioid receptors. The combined exposure to morphine 
enhanced the effect of Tat to release cytokines and chemokines which are involved in 
perpetuating the immune response (Zou et al., 2011). CCL2 is a chemokine that recruits 
macrophages and microglia (Ansari et al., 2011). IL-6 upregulates HIV production in in 
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acutely and chronically infected monocytic cells.  IL-6 also acts synergistically with TNF-
a to stimulate HIV production and increase transcription of the viral RNA (Poli et al., 
1990). The exaggerated cytokines produced in response to morphine and Tat are 
differential among CNS regions. For example, glia isolated from the striatum have a 
pronounced effect compared to those from the cerebral cortex and cerebellum (Fitting et 
al., 2010). Glia expressing MOR act as a critical convergence point for the additive 
effects. 
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Chapter 2 
OVERVIEW OF THE SPHINGOSINE-1-PHOSPHATE RECEPTOR-1 
2.1 Sphingosine-1 phosphate and signaling 
 Sphingosine-1-phosphate (S1P) is a sphingolipid metabolite regulating many 
physiological functions such as cell growth and proliferation, cell motility, and 
lymphocyte trafficking. S1P is the natural endogenous ligand for the sphingosine-1-
phosphate receptors (S1PRs). However, apart from signaling through the receptors, 
S1P can act as an intracellular second messenger in cell proliferation, suppression of 
apoptosis, and mobilization of calcium from internal stores (An et al., 2000; Strub et al., 
2010; Payne et al., 2002). Notably, S1P is associated with many cellular processes 
critical for regulating immune function such as lymphocyte trafficking and 
cytokine/chemokine production (Chi et al., 2011; Garris et al., 2014). S1P formation 
occurs through phosphorylation of the sphingosine component localized in the 
sphingolipid backbone of the plasma membrane (Zheng et al., 2006; Merrill et al., 
2011). The phosphorylation reaction is catalyzed by sphingosine kinase 1 and 2 (Sphk1 
and Sphk2) (Hait et al., 2006; Neubaeur et al., 2013). A stimulus such as a pro-
inflammatory cytokine, TNF-a, will activate the Sphk1 and lead to the production of the 
phosphorylated ligand which can act in an autocrine or paracrine manner (Takabe et al., 
2008; Rosen et al., 2005). S1P can bind to five G protein-coupled receptors (GPCR), 
designated S1PR1-5 which are expressed ubiquitously (Means et al., 2009). Each of the 
GPCRs is coupled to different classes of G proteins: S1PR1is coupled primarily to Gi/o, 
S1PR2 and S1PR3 can be coupled to Gi/o, Gq, G12/13, and S1PR4 can couple through 
activates Gi/o. and G12/13 (Kluk et al., 2002). The relative expression of S1PRs and 
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specific G protein signaling pathways can influence the functional response to S1P 
(Windh et al., 1999; Siehler et al., 2002). 
2.2 S1PR1 and Central Nervous System Inflammation  
In the CNS, all cell types express four of the five S1PRs. However, expression 
levels of the different receptor subtypes vary between different cells. Neurons 
predominantly express S1PR1 and S1PR3, astrocytes principally S1PR1 and S1PR3, and 
microglia mainly express S1PR1 and S1PR2 (Nicimura et al., 2010; Farez et al., 2016). 
Much of the role of the S1P-S1PR, ligand-receptor, interactions in the nervous system 
have been investigated after the discovery and use of a S1P structural analog, 
fingolimod, in treating multiple sclerosis (MS) (Park et al., 2017). Fingolimod is a S1P 
modulator that can readily access the CNS. Astrocytes, microglia, and proinflammatory 
monocytes contribute to demyelination, scar formation, and neurodegeneration. In an 
experimental autoimmune encephalomyelitis (EAE) model of chronic inflammation, 
treatment with fingolimod decreased production of proinflammatory mediators by 
astrocytes (Rothhammer et al., 2017). Intracerebral fingolimod injection studies have 
demonstrated that the drug’s beneficial effects are mediated through the S1P1 
expressing astrocytes. Administration of fingolimod results in downregulation of the S1P 
receptors and this reduces the astroglial-mediated neuroinflammatory effects (Choi et 
al., 2011; Wu et al., 2013). Microglia express all of the receptors except S1PR4, and 
activation of microglia leads to generation of nitric oxide metabolites, proinflammatory 
cytokines such as TNF-a, and caspases which were all reduced by fingolimod (Aktas et 
al., 2010; Jackson et al., 2011). S1P receptors have been potential targets for 
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modulating CNS inflammation driven by astrocytes and microglia (Rothhammer et al., 
2017). 
2.3 S1PR modulators  
 Many pharmacological tools targeting the S1PRs have been developed to 
thoroughly understand the role of S1P signaling in normal neural functions. Among 
them include fingolimod (FTY720), SEW 2871, and W146. Fingolimod was the first oral 
drug approved by the Food and Drug Administration for relapsing-remitting MS (Sharma 
et al., 2011; Chun et al., 2011; Kappos et al., 2006). Clinical efficacy of the drug results 
from modulating S1PR1, leading to sequestration of lymphocytes in the lymph nodes 
and ultimately reduced trafficking of autoreactive lymphocytes to the CNS (Subei et al., 
2015; Hunter et al., 2016). Fingolimod is a structural analog of sphingosine that also is 
phosphorylated by sphingosine kinase 1 and 2. Fingolimod phosphate (pFTY720) 
activates S1PR1,3,4,5, and it activates S1PR1 with high potency compared to S1P (Shaikh 
et al., 2015; Shmyrev et al., 2012; Brinkmann et al., 2002). Persistent activation of 
S1PR1 by FTY720 results in the desensitization, internalization, and then degradation of 
the receptor (Wu et al., 2013; Mullershausen et al., 2009). The therapeutic effects of the 
drug can be attributed to the ubiquitination and degradation of the receptor which can 
modulate proinflammatory pathways. Similar to the natural ligand S1P, SEW 2871, a 
selective S1PR1 agonist, leads to receptor recycling instead of degradation (Jo et al., 
2005). This agonist does not have any effects at the other four receptors (Watters et al., 
2011). W146 is a selective antagonist that inhibits S1P and SEW 2871 mediated S1PR1 
activation (Gonzalez-Cabrera et al., 2008).  
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Chapter 3 
MATERIALS AND METHODS 
3.1 Astroglial cell cultures  
 Primary mixed-glial cultures were prepared from ICR mice (Charles River Inc., 
Charles River, MA) and Beta-arrestin 2 knockout (breeding pairs obtained from Dr. 
Lefkowitz, Duke University and housed within VCU transgenic core) at postnatal day 0-1 
as previously established. In brief, whole brains were extracted and finely minced in 
serum-free Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen-Gibco) before 
being incubated with 2.5 mg/mL trypsin (Sigma, St. Louis, MO) and 0.015 mg/mL 
DNase (Sigma) (30 min, 37°C). Tissue was triturated with a 10-mL pipette, filtered 
through a nylon membrane with 100 µm pores, centrifuged (5 min at 1000 rpm), and re-
suspended in DMEM supplemented with 10% fetal bovine serum (Thermo Scientific 
Hyclone, Logan, UT), 6 g/L glucose (Sigma), 3.75% sodium bicarbonate (Life 
Technologies), and penicillin (Life Technologies). This was repeated again using a 5-mL 
pipette and a 30 µm pore diameter nylon filter. Viable cells were counted using trypan 
blue dye exclusion staining and plated at 70,000 cells/cm2 in 24-well cell culture plates 
for protein quantification (Costar, Corning Life Sciences; Acton, MA), or in poly-L-lysine-
coated glass bottom multi-well plates for cell viability assays (MatTek Corporation, 
Ashland, MA). Media was changed every 2-3 d under conditions of 37 °C and 5% 
CO2:95% air until cells were ~80% confluent. Cultures reached this level of confluence 
within 7-9 days. Represented cultures were primarily astrocytes and some microglia as 
determined by immunostaining for glial fibrillary acidic protein.  
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3.2 Experimental treatments  
 Individual cell culture wells were continuously exposed to medium alone, 
morphine sulfate (NIDA Drug Supply System, Rockville, MD; 500 nM) and/or HIV-1 
Tat1-86 (transactivator of tat; ImmunoDX, Woburn, MA; 100 nM) in the presence or 
absence of S1PR1 modulators: FTY720 (gift from Dr. Aaron Lichtman, VCU; Cayman 
Chemicals; 0.1 nM-1 µM, FTY720-phosphate (gift from Dr. Laura Sim-Selley, VCU; 
Cayman Chemicals; 1 µM), W146 (Cayman Chemicals; 0.1 nM-1 µM), SEW 2871 (gift 
from Dr. Laura Sim-Selley, VCU; 0.1 nM-1 µM). The powdered form of FTY720, 
FTY720-phosphate, and SEW 2871 was reconstituted in 100% ethanol and final 
treatment concentrations were below 1%. W146 powder was reconstituted in DMSO 
and the final concentration was maintained below 0.1%. Additionally, some wells were 
treated with vehicle controls: DMSO and ethanol as a control group. The Tat 
recombinant protein is produced in the E. coli expression system and purified by ion 
affinity and reverse phase HPLC to >99% purity (verified by SDS-PAGE and HPLC). 
Low retention pipette tips were used to reconstitute the lyophilized powder was 
reconstituted in ultrapure water. 
When the cells were concurrently treated, the S1PR1 agonists/antagonists were 
added prior to Tat ± morphine. To measure concentration and time-dependent effects, 
cells were pretreated with various concentrations of S1PR1 agonists/antagonists for 0.5, 
1, 2, 4, 12, or 24 h, after which the cells were exposed to Tat and morphine for an 
additional 12 h. To avoid complicating results with increasing autocrine and paracrine 
signaling effects, longer Tat and morphine exposure times were not tested. 
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3.3 Enzyme-linked immunosorbent assay  
Changes in cytokine and chemokine levels secreted in the culture supernatants 
were detected using ELISA kits: CCL2 (Biolegend), IL-6 (Biolegend), CCL3 (R&D 
Systems), CCL4 (R&D Systems).  Conditioned culture medium was harvested 
centrifuged at 1,500 rpm for 10 minutes at 4 °C. Samples not immediately used were 
aliquoted and stored at −80 °C. Samples were diluted two-fold prior to incubating on 
coated plates. Appropriate standard curves were used to determine protein levels 
(absorbance at 450 nm). Samples were measured and blank values were subtracted 
from the readings.  
3.4 Cell viability assay  
 The viability of the glia after treatment with S1PR1 agonists, antagonists, or 
vehicle was confirmed using the LIVE/DEAD Viability/Cytotoxicity Kit (Life 
Technologies). To prepare the working solution, ethidium homodimer-2 (EthD-2) nucleic 
acid stain (20% DMSO) was diluted 1:500 in the medium. EthD-2 a cell impermeable 
fluorescent dye that stains for non-viable cells with compromised membranes. Hoechst 
33342 was added to the medium (1:10,000 dilution) to stain nuclei. The cells were 
washed with HBSS three times and covered in fresh growth medium. Immediately 
afterwards, the cells were imaged using confocal microscopy Zeiss. For each well, 200 
cells (Hoechst 33342-positive cells) were manually counted. The proportion of red-
labeled cells per Hoechst-labeling, was used as an index for non-viable cells.  
3.5 Statistical Analysis  
 Statistical analyses were done by 2-way analysis of variance (ANOVA) followed 
by Tukey post-hoc testing using GraphPad Prism 7 software (La Jolla, CA).  
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Chapter 4 
RESULTS 
4.1 pFTY720 attenuates Tat and morphine induced release of IL-6 and CCL2 
            To confirm that the mixed glial cultures respond to viral proteins and morphine, 
confluent cultures were pretreated with 100 nM Tat and 500 nM morphine either alone 
or in combination. As mentioned previously, the exposure times were limited to 12 h to 
avoid the possible over-accumulation of inflammatory molecules that might artificially 
drive the excessive production of cytokines via exaggerated resulting in autocrine and 
paracrine feedback in vitro. As a measure of heightened inflammatory response, 
conditioned medium secreted from the glial cultures was harvested to measure levels of 
the proinflammatory cytokine IL-6 and the chemokine CCL2 secreted by the glia. Both 
IL-6 and CCL2 levels were elevated in the Tat-treated groups compared to the 
untreated control groups. As previously demonstrated by El-Hage et al., 2008, 
concurrent exposure to viral proteins and morphine potentiated the response (p < 
0.0001) (Figure 1).   
FTY720, a sphingosine-1-phosphate (S1PR1,3,4,5) modulator, was used to 
investigate the role of these receptors in regulating this inflammatory response (Figure 
1). The phosphorylated form of FTY720 (pFTY720) is the active metabolite, which has 
been suggested to mediate its neuroinflammatory effects. Glial cultures pre-treated with 
pFTY720 (1 µM) for 12 h, pFTY720 significantly reduced Tat ± morphine-induced 
release of IL-6 and CCL2 (p < 0.0001). There were no significant differences between 
the vehicle control (< 1% ethanol) and the untreated groups that lacked pFY720. 
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4.2 FTY720 reduces Tat and morphine induced release of IL-6, CCL2, CCL3, CCL4 
in a concentration-dependent manner    
 The oral tablet formulation of fingolimod (FTY720) is the non-phosphorylated 
form of the drug. This highly lipophilic prodrug crosses the blood-brain barrier and 
accumulates in the brain and spinal cord before being converted to the phosphorylated 
active form (Cipriani et al., 2015). To assess the effects of direct fingolimod exposure on 
glia, the mixed-glial cultures were pretreated for 12 h with FTY720 before adding Tat 
and/or morphine. The release of the chemokines CCL3 and CCL4 were examined in 
addition to IL-6 and CCL2 to expand the scope of the inflammatory response. Tat or Tat 
+ morphine exposure significantly enhanced CCL2, CCL3, and CCL4 levels (p < 
0.0001) (Figure 2). As seen with 1 µM pFTY720, treatment with FTY720 (1 µM) 
significantly attenuated both the Tat or combined Tat and morphine induced increases 
in cytokine and chemokine production by mixed-glia (p < 0.0001) (Figure 2). In fact, 
FTY720 concentration-dependently reduced levels of all three chemokines in cells 
challenged with both Tat or combined Tat and morphine (Figure 3). Pretreatment with 
0.1 nM FTY720 significantly reduced Tat-dependent increases in the release of CCL2, 
CCL3, and CCL4 from mixed-glial cultures compared to cultures treated with Tat ± 
morphine by themselves. 
4.3 W146 reverses the inhibitory effects of FTY720 on Tat and morphine induced 
CCL2, CCL3, and CCL4 release  
W146 is a S1PR1 antagonist that does not have agonist or antagonist activity at 
the other S1PRs. The antagonist has been previously shown to displace pFTY720 
bound to the receptor and ultimately act as a competitive antagonist (Mullershausen et 
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al., 2009). The selective antagonist in combination with the FTY720 can provide more 
evidence that immunomodulatory effects are mediated primarily through S1PR1.  
To measure the effects of W146 on cytokine secretion, the antagonist (1 µM) was 
added to the cell cultures prior to Tat and/or morphine treatments. W146 alone 
attenuates the release of CCL2, CCL3, and CCL4. This effect is significantly different 
from the effect of FTY720 (p < 0.0001).  In addition to treating cultures with FTY720, 
W146 was added to cultures for 1 h before treating with FTY720 for 12 h.  By itself, 
FTY720 reduced CCL2 levels in a concentration-dependent manner in both the Tat and 
in the combined Tat and morphine groups. In the presence of both FTY720 and W146, 
the concentration-effect curve gradually shifted to the right with higher W146 
concentrations (Figure 5).  
4.4 Time-dependent FTY720 and SEW2871 effects 
 S1PR1s can undergo internalization and classic downregulation in response to 
sustained receptor activation. The time-dependent decrease in the density of S1PR1s at 
the cell surface reduces the cell’s sensitivity to ligands. FTY720 exerts its effects by 
downregulating membrane-associated S1PR1s instead of recycling them back to the 
plasma membrane as seen with the natural ligand. Another S1PR1 modulator, 
SEW2871, is a S1PR1 selective agonist that has no known effects at the other four S1P 
receptors. Much like S1P, SEW2871 acts at S1PR1s, and prolonged SEW2871 
exposure results in the recycling of the receptor to the plasma membrane. To 
investigate whether FTY720 was acting as a functional antagonist, the cultures were 
treated with varying concentrations of FTY720 (Figure 6) and SEW2871 (Figure 7) for 
different time intervals before introducing Tat or morphine. The CCL2, CCL3, and CCL4 
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levels were sampled after pretreating for 0.5, 1, 2, 4, 12, and 24 h durations. Glial 
cultures that were incubated for 0.5, 1, and 2 h showed decreased chemokine levels. 
With either drug, incubation periods longer than 4 h displayed an increase in chemokine 
levels. In the case of SEW2871, longer exposure to the drug resulted in a gradual 
increase in chemokine levels that are comparable to untreated control groups (Tat 
alone) (Figure 7). The differential effects of FTY720 and SEW2871 are displayed in 
Figure 8. Significant differences in elevation of chemokine levels were first observed 
with cells treated for 4 h.  
4.5 FTY720 did not significantly affect glial viability 
 To examine if the reduction in the cytokine levels was due to FTY720 effects the 
viability of the cells, the cultures were treated with an ethidium homodimer nucleic acid 
staining agent after exposure to the drug for either 24 or 48 h. This red stain is cell-
impermeant, and only dying cells with compromised membranes are labeled. At both 24 
h and 48 h only 3% of the cells were either non-viable or in the process of dying, while 
the remainder were calcein positive (green fluorescence) indicating that over 97% of the 
cells were viable (Figure 9).    
4.6 Knockout of Beta-arrestin 2 in glia blocks the FTY720 effects 
After pro-longed exposure to FTY720, the receptor is functionally downregulated 
which involves recruitment of b-arrestin leading to ubiquitination and degradation of 
S1PR1 (Sykes et al., 2014; Oo et al., 2014).  These adaptor proteins are highly 
expressed in the brain and form complexes with most G-protein-coupled receptors 
(GPCRs) after a prolonged administration of an agonist. Binding between the b-arrestin 
and the GPCR prevents coupling to G proteins and targets receptors to clathrin-
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mediated endocytosis (Tian et al., 2014; Sykes et al. 2014) demonstrated that FTY720 
stimulates an higher level of b-arrestin recruitment compared to S1P. The role of b-
arrestin 2 in the FTY720-mediated decreases in chemokine levels was investigated 
using glial cultures derived from b-arrestin 2 knockout mice. Although the average CCL2 
levels were lower in both the Tat and the combined Tat and morphine groups treated 
with FTY720 for 12 h, there were no significant differences compared to the vehicle-
treated group (Figure 10).  
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Figure 1. Effects of pFTY720 on Tat ± morphine-induced increases in IL-6 and 
CCL2 production by glia. Mixed glial cultures were treated with pFTY720 (1 µM for 12 
h) prior to adding Tat ± morphine. Exposure to Tat (100 nM for 12 h) enhanced IL-6 and 
CCL2 levels, and the addition of morphine (500 nM) significantly potentiated this effect. 
Pre-treatment of mixed glia with pFTY720 significantly reduced Tat ± morphine-
mediated levels of IL-6 and CCL2. Absolute levels of IL-6 and CCL2 were measured by 
ELISA (n = 4 experiments with two technical replicates per experiment). Values are 
represented as mean ± SD (# p < 0.0001 Tat vs. Tat ± morphine; **** p < 0.0001 vs. 0 
nM pFTY720).  
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Figure 2. Effects of FTY720 on Tat ± morphine-induced increases on IL-6, CCL2, 
CCL3, and CCL4 production by glia. Pre-treatment of mixed glia with FTY720 (1 µM 
for 12 h) significantly attenuated Tat (100 nM) ± morphine (500 nM)-induced levels of IL-
6, CCL2, CCL3, and CCL4. Graphs show representative data of 4 separate experiments 
(n = 4) with two replicates per experiment. Values are represented as pg/mL ± SD (# p 
< 0.0001 Tat vs. Tat ± morphine;**** p < 0.0001 vs. 0 nM FTY720). 
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Figure 3. Concentration-dependent effects of FTY720 on Tat ± morphine-induced 
increases in CCL2, CCL3, and CCL4 production by glia. Mixed glial cultures were 
pre-treated with FTY720 in concentrations of 0.1, 1, 10, 100, 1 µM or with vehicle before 
being challenged with Tat ± morphine. A significant attenuation in Tat (A) or combined 
Tat and morphine (B)-induced increases in cytokine or chemokine levels was first 
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observed at the lowest FTY720 (0.1 nM) concentration tested.  Cytokine levels 
gradually reduced with increasing concentrations of FTY720. Graphs show 
representative data of 4 separate experiments (n = 4) with two replicates per 
experiment. Values are represented as pg/mL ± SD (* p < 0.05 vs. 0 nM FTY720; *** p 
< 0.001 vs. 0 nM FTY720; **** p < 0.0001 vs. 0 nM FTY720). 
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Figure 4. Effects of W146 on Tat ± morphine-induced increases on CCL2, CCL3, 
and CCL4 production by glia. Pre-treatment with a S1PR1-selective antagonist W146 
(1 µM for 12 h) significantly attenuated Tat ± morphine-induced levels of chemokines 
CCL2, CCL3, and CCL4. FTY720 1 µM for 12 h also reduced chemokine secretion. 
Graphs show representative data of 4 separate experiments (n = 4) with two replicates 
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per experiment. Values are represented as pg/mL ± SD (**** p < 0.0001 vs. 0 nM 
FTY720).  
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 Figure 5. Effects of W146 pretreatment on FTY720-dependent reductions in Tat ± 
morphine-induced increases in CCL2 production by glia. Glial cultures were pre-
treated with W146 (0, 1, 10, 100, 1 µM for 1 h) before adding FTY720 (0.1, 1, 10, 100, 1 
µM for 12 h). FTY720 concentration-dependently reduced CCL2 levels in cells treated 
with Tat alone (A) or Tat ± morphine (B). W146 inhibited the effects of FTY720, and a 
rightward shift in the FTY720 concentration-effect curve was observed in the presence 
of increasing concentrations of W146. Graphs show representative data of 4 separate 
experiments (n = 4) with two replicates per experiment. Values are represented as 
pg/mL ± SD (* p < 0.0001 vs. 0 nM FTY720). 
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Figure 6. Effect of the duration of FTY720 pretreatment on Tat-induced cytokine 
production by glia. Mixed glial cultures were pre-treated with FTY720 (0.1, 1, 10, 100, 
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1 µM) for different durations (0.5, 1, 2, 4, 12, and 24 h) before adding Tat (100 nM for 12 
h). At earlier time points (0.5 and 1 h), CCL2, CCL3, and CCL4 levels were reduced. An 
increase in the protein levels was observed starting at 4 h (A-C). Graphs show 
representative data of 4 separate experiments (n = 4) with two replicates per 
experiment. Values are represented as pg/mL ± SD.  
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Figure 7. Effect of the duration of SEW 2871 pretreatment on Tat-induced cytokine 
production by glia. Mixed glial cultures were pre-treated with SEW 2871 (0.1, 1, 10, 
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100, 1 µM) for different time intervals (0.5, 1, 2, 4, 12, and 24 h) before adding Tat (100 
nM; 12 h). At earlier time points (0.5 and 1 h), CCL2, CCL3, and CCL4 levels were 
reduced. An increase in the CCL2 levels was observed starting at 4 h (A) and an 
increase in CCL3 and CCL4 levels was first observed after pretreatment for 2 h (B-C). 
Graphs show representative data of 4 separate experiments (n = 4) with two replicates 
per experiment. Values are represented as pg/mL ± SD. 
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Figure 8. Comparison of the effect FTY720 and SEW 2871 pretreatment on CCL2, 
CCL3, and CCL4 production by glia. Mixed glial cultures were pretreated with either 
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FTY720 (1 µM) or SEW 2871 (1 µM) for 0.5 h up to 24 h before adding Tat (100 nM; 12 
h). Both S1PR1 modulators reduced the Tat-mediated levels of CCL2, CCL3, and CCL4 
with shorter exposure periods. An increase in protein levels was observed with longer 
exposure. Graphs show representative data of 4 separate experiments (n = 4) with two 
replicates per experiment. Values are represented as pg/mL ± SD (*p < 0.05 vs. 1 µM; 
**** p < 0.0001 vs. 1 µM FTY720). 
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Figure 9. FTY720 did not significantly affect glial viability. Glia at day 7 were treated 
with 100, 300, 1 µM FTY720 for 24 (A) and 48 h (B). FTY720 did not have any 
significant cytotoxic effects. Graphs show representative data of 4 separate experiments 
(n = 4); >200 cells were counted per group in each experiment.  
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Figure 10. Effect of FTY720 on CCL2 levels in wildtype and β-arrestin 2 KO glia 
after treatment with Tat ± morphine. Mixed glial cultures derived from wild type (A) 
and b-arrestin 2 KO (B) mice were pretreated with FTY720 prior to adding Tat and 
morphine. No significant difference was observed between FTY720- and vehicle- 
treated groups. Graphs show representative data of 4 separate experiments (n = 4) with 
two replicates per experiment. Values are represented as pg/mL ± SD.  
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Chapter 5 
DISCUSSION  
The results from the present studies confirm prior findings that morphine 
exaggerates the effects of Tat while by itself morphine has few effects on cytokine 
production by astrocytes. Tat alone increased release of IL-6, CCL2, CCL3, and CCL4, 
and addition of morphine significantly potentiated these effects (Figs. 1 and 2). The 
potential therapeutic immunomodulatory function of FTY720 led us to analyze the 
effects of the compound on Tat-induced release of IL-6, CCL2, CCL3, and CCL4. 
Primary mixed glia cultures were treated with either the prodrug FTY720 or the active 
form pFTY720 to understand the differential effects of both forms of the drug. 
Phosphorylated FTY720 is an agonist with a high level of intrinsic activity that elicits 
persistent internalization of S1PR1s. Cytokines and chemokines are inflammatory 
products that regulate communication between astrocytes, microglia, and leukocytes 
during CNS inflammation. States of chronic inflammation induced by CNS insults are 
often accompanied by prolonged activation of glia. Upon exposure to HIV-1 Tat, co-
cultures of neurons and glia have displayed reduced neuron survival.  Glia drive the 
interactive neurotoxic effects of combined Tat and morphine (Zou et al., 2011). Prior 
studies established that Tat induces cytokine production in astrocytes in a [Ca2+]i and 
NF-kB dependent manner, while morphine potentiates the effects of Tat through further 
increases in [Ca2+]i and subsequent translocation of the p65 subunit of NF-kB to the 
nucleus (El-Hage et al., 2008). 
The data presented here shows that pre-incubation with pFTY720 or FTY720 
inhibits both the Tat and combined Tat and morphine-induced release of 
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proinflammatory cytokines. This effect was detected at nanomolar concentrations of 
FTY720 and was dependent on the concentration such that the largest reduction in 
cytokine levels was at the highest concentration tested (Fig. 3). Specificity of the 
receptor involved was analyzed using W146, a competitive S1PR1-specific antagonist. 
W146 alone significantly inhibits CCL2, CCL3, and CCL4 levels, albeit not as effectively 
as FTY720 (Fig. 4). With increasing concentrations of W146, the FTY720 concentration-
effect curve gradually shifted to the right (Fig. 5). The shift in FTY720 potency suggests 
S1PR1 mediated the changes in chemokine release. These results provide further 
support to the hypothesis that the S1P-S1PR signaling pathway is involved in regulating 
the release of pro-inflammatory molecules from astrocytes.  
The therapeutic activity of FTY720 is attributed to the drug’s ability to cause S1P 
receptor internalization and degradation. Unlike the agonists S1P and SEW 2871, which 
cause S1P receptors to recycle back to the plasma membrane, FTY720-induced S1P 
receptor activation appears to downregulate the receptor—limiting the number of S1P 
receptors at the cell surface and the responsiveness to S1P or other agonists. This 
mechanism of action was reflected in the time-course studies where exposure up to 4 h 
with either FTY720 or SEW 2871 inhibited Tat-induced increases in CCL2, CCL3, and 
CCL4. Greater than 4 h pretreatment with SEW 2871 led to time-dependent increases 
in all three chemokines in response to Tat that were significantly greater than 
pretreatment with FTY720 (Figures 6-8).  One of the possible explanations for this 
different response is that the continuous exposure to FTY720 after the addition of Tat 
may lead to persistent receptor internalization and degradation. Furthermore, FTY720 
and SEW 2871 may be actively stimulating the Gi/o, ERK, Akt, and Rac signaling 
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pathways via S1PR1 (Jo et al., 2005).  Moreover, some de novo S1P receptor synthesis 
may be occurring during the, and receptor recycling is readily happening at the same 
time with SEW 2871. The pronounced increase in protein levels was not observed with 
FTY720, suggesting that receptors were degraded which had a longer lasting impact on 
S1P signaling. The process of internalization appears to require b-arrestin recruitment. 
The CCL2 level in b-arrestin 2 KO glia exposed to FTY720 was comparable to the 
control group (Fig. 10).  
The S1PR1 receptor is a novel target investigated in these studies to inhibit 
elevated cytokine secretion induced by Tat alone and Tat combined with morphine. The 
role of S1P- S1PR1 signaling in downstream of cytokine secretion was demonstrated 
using conditional null mutant mice lacking the S1PR1 receptor in astrocytes. When 
inflammation was induced in these subjects, production of inflammatory cytokine levels 
(IL-1b, IL-6, IL-17) was reduced. Comparable to S1PR1 knockout mice, wildtype mice 
exposed to FTY720 reduced S1PR1 signaling. Thus, FTY720 appears to act as a 
functional antagonist by downregulating S1PR1 surface receptors and reducing 
extracellular S1P signaling on astrocytes (Choi et al., 2011). These results were 
recapitulated in vitro with primary murine astrocyte cultures. Treatment with FTY720 
decreased the expression of proinflammatory cytokines and chemokines in the 
astrocytes activated with LPS (O’Sullivan et al., 2018).  
Astrocytes are involved in the S1P signaling pathway not only because they 
express S1P receptors, but also since they synthesize and release S1P (Anelli et al., 
2005). The secreted S1P can either activate the astrocyte in an autocrine manner or 
active neighboring glia or neurons. S1P signaling involves downstream NF-κB shuttling 
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to the nucleus and nitric oxide production in astrocytes. Under proinflammatory 
conditions, the sphingosine kinases are upregulated and cytokines such as TNF-a can 
promote translocation to the plasma membrane leading to enhanced generation of S1P 
which can signal in the autocrine and paracrine pathways (Snider et al., 2010; Takabe 
et al., 2008). 
It is important to emphasize that FTY720 also has affinity for other S1PRs, and 
additional studies isolating each specific receptor are needed to clarify the role of the 
different receptors. The possible explanation for the change in immune response is the 
ability of FTY720 to block NF-κB nuclear translocation induced by Tat ± morphine. The 
Tat-induced increases in cytokine production can result in activation of sphingosine 
kinases. Cytokines stimulate sphingosine kinases which leads to increased intracellular 
S1P levels that can be secreted out of the cell and act through the S1P receptors, 
inducing “inside-out” S1P signaling involved in NF-κB activation.  
Overall, the data demonstrate that glial responsiveness to Tat ± morphine include 
enhanced production of proinflammatory cytokines and chemokines. Both the 
phosphorylated and non-phosphorylated form of FTY720 attenuate the immune 
response. W146 blocked FTY720-mediated effects suggesting S1PR1 is likely 
responsible for modulating that Tat-induced cytokine release. A significant increase in 
protein levels was observed with longer SEW 2871 pretreatments compared to FTY720, 
supporting the concept that FTY720 acts as a functional antagonist. It is critical to note 
that though the cultures in these studies consist mainly of astrocytes, the existing low 
levels of microglia also release inflammatory factors that activate astrocytes. Both 
astrocytes and microglia express S1PRs, so additional studies are needed to determine 
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how S1P signaling is influencing Tat-induced cytokine release from various types of 
glia—especially astroglia and microglia. The results suggest that S1P receptors are a 
potential therapeutic target in regulating the Tat-induced immune response.  
  
 43 
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